368
Views
18
CrossRef citations to date
0
Altmetric
Brief Report

Pharmacogenomic predictors of citalopram treatment outcome in major depressive disorder

, , &
Pages 135-144 | Received 08 Feb 2012, Accepted 09 Jan 2013, Published online: 26 Mar 2013

References

  • Akiskal HS. 1982. Factors associated with incomplete recovery in primary depressive illness. J Clin Psychiatry 43:266–271.
  • Alda M, Grof P, Grof E, Zvolsky P, Walsh M. 1994. Mode of inheritance in families of patients with lithium-responsive affective disorders. Acta Psychiatr Scand 90:304–310.
  • Anisman H, Merali Z. 2003. Cytokines, stress and depressive illness: brain-immune interactions. Ann Med 35:2–11.
  • Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. 2004. Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. J Clin Invest 113:253–264.
  • Belzeaux R, Formisano-Treziny C, Loundou A, Boyer L, Gabert J, Samuelian JC, et al. 2010. Clinical variations modulate patterns of gene expression and define blood biomarkers in major depression. J Psychiatr Res 44:1205–1213.
  • Carlin AF, Uchiyama S, Chang YC, Lewis AL, Nizet V, Varki A. 2009. Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response. Blood 113:3333–3336.
  • Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, et al. 2013. Candidate Genes Expression Profile Associated with Antidepressants Response in the GENDEP Study: Differentiating between Baseline ‘Predictors’ and Longitudinal ‘Targets’. Neuropsychopharmacology 38:377 85.
  • Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al. 2003. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362–369.
  • Chen GY, Tang J, Zheng P, Liu Y. 2009. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 323:1722–1725.
  • Crocker PR, Paulson JC, Varki A. 2007. Siglecs and their roles in the immune system. Nat Rev Immunol 7:255–266.
  • Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. 2003. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4:3.
  • Franchini L, Serretti A, Gasperini M, Smeraldi E. 1998. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res 32:255–259.
  • Gladkevich A, Kauffman HF, Korf J. 2004. Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 28:559–576.
  • Glatt SJ, Everall IP, Kremen WS, Corbeil J, Sasik R, Khanlou N, et al. 2005. Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. Proc Natl Acad Sci USA 102:15533–15538.
  • Grof P, Alda M, Grof E, Zvolsky P, Walsh M. 1994. Lithium response and genetics of affective disorders. J Affect Disord 32:85–95.
  • Huang DW, Sherman BT, Lempicki RA. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:44–57.
  • Isacsson G, Rich CL, Jureidini J, Raven M. 2010. The increased use of antidepressants has contributed to the worldwide reduction in suicide rates. Br J Psychiatry 196:429–433.
  • Kemp AH, Gordon E, Rush AJ, Williams LM. 2008. Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. CNS Spectr 13:1066–1086.
  • Kittleson MM, Minhas KM, Irizarry RA, Ye SQ, Edness G, Breton E, et al. 2005. Gene expression in giant cell myocarditis: Altered expression of immune response genes. Int J Cardiol 102:333–340.
  • Kubera M, Simbirtsev A, Mathison R, Maes M. 2000. Effects of repeated fluoxetine and citalopram administration on cytokine release in C57BL/6 mice. Psychiatry Res 96:255–266.
  • Kubera M, Lin AH, Kenis G, Bosmans E, van BD, Maes M. 2001. Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol 21:199–206.
  • Maes M. 1995. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 19:11–38.
  • Maes M. 2001. The immunoregulatory effects of antidepressants. Hum Psychopharmacol 16:95–103.
  • Malki K, Lourdusamy A, Binder E, Paya-Cano J, Sluyter F, Craig I, et al. 2012. Antidepressant-dependent mRNA changes in mouse associated with hippocampal neurogenesis in a mouse model of depression. Pharmacogenet Genomics 22:765–776.
  • Mamdani F, Berlim MT, Beaulieu M-M, Labbe A, Merette C, Turecki G. 2011. Gene expression biomarkers of response to citalopram treatment in major depressive disorder. Translational Psychiatry 1:e13.
  • Marziliano N, Grasso M, Pilotto A, Porcu E, Tagliani M, Disabella E, et al. 2009. Transcriptomic and proteomic analysis in the cardiovascular setting: unravelling the disease?J Cardiovasc Med (Hagerstown ) 10:433–442.
  • Matkovich SJ, Van Booven DJ, Youker KA, Torre-Amione G, Diwan A, Eschenbacher WH, et al. 2009. Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation 119:1263–1271.
  • Mendlewicz J, Fieve RR, Stallone F, Fleiss JL. 1972. Genetic history as a predictor of lithium response in manic-depressive illness. Lancet 1:599–600.
  • Mendlewicz J, Fieve RR, Stallone F. 1973. Relationship between the effectiveness of lithium therapy and family history. Am J Psychiatry 130:1011–1013.
  • Mill J, Asherson P, Browes C, D’Souza U, Craig I. 2002. Expression of the dopamine transporter gene is regulated by the 3’ UTR VNTR: Evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet 114:975–979.
  • Murray CJL, Lopez AD. 1998. The global burden of disease. Geneva: WHO.
  • Myint AM, Leonard BE, Steinbusch HW, Kim YK. 2005. Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord 88:167–173.
  • Nagasaki K, Miki Y. 2008. Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer. Breast Cancer 15:117–120.
  • Nicholson AC, Unger ER, Mangalathu R, Ojaniemi H, Vernon SD. 2004. Exploration of neuroendocrine and immune gene expression in peripheral blood mononuclear cells. Brain Res Mol Brain Res 129:193–197.
  • Pare CM, Rees L, Sainsbury MJ. 1962. Differentiation of two genetically specific types of depression by the response to anti-depressants. Lancet 2:1340–1343.
  • Rollins B, Martin MV, Morgan L, Vawter MP. 2010. Analysis of whole genome biomarker expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 153B:919–936.
  • Rush AJ, Trivedi M, Fava M. 2003. Depression, IV: STAR*D treatment trial for depression. Am J Psychiatry 160:237.
  • Salminen A, Kaarniranta K. 2009. Siglec receptors and hiding plaques in Alzheimer’s disease. J Mol Med 87:697–701.
  • Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. 2008. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299:425–436.
  • Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H. 1996. Increased CD56+ natural killer cells and related cytokines in major depression. Clin Immunol Immunopathol 78:83–85.
  • Sequeira A, Gwadry FG, Ffrench-Mullen JM, Canetti L, Gingras Y, Casero RA, Jr., et al. 2006. Implication of SSAT by gene expression and genetic variation in suicide and major depression. Arch Gen Psychiatry 63:35–48.
  • Sequeira A, Mamdani F, Ernst C, Vawter MP, Bunney WE, Lebel V, et al. 2009. Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS One 4:e6585.
  • Serretti A, Franchini L, Gasperini M, Rampoldi R, Smeraldi E. 1998. Mode of inheritance in mood disorder families according to fluvoxamine response. Acta Psychiatr Scand 98:443–450.
  • Sharp FR, Lit L, Xu H, Apperson M, Walker W, Wong B, et al. 2006. Genomics of brain and blood: progress and pitfalls. Epilepsia 47:1603–1607.
  • Streiner DL. 2002. Breaking up is hard to do: the heartbreak of dichotomizing continuous data. Can J Psychiatry 47:262–266.
  • Tang S, Shen YJ, DeBellard ME, Mukhopadhyay G, Salzer JL, Crocker PR, et al. 1997. Myelin-associated glycoprotein interacts with neurons via a sialic acid binding site at ARG118 and a distinct neurite inhibition site. J Cell Biol 138:1355–1366.
  • Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. 2006. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28–40.
  • Wang Y, Neumann H. 2010. Alleviation of neurotoxicity by microglial human Siglec-11. J Neurosci 30:3482–3488.
  • Wicks SJ, Grocott T, Haros K, Maillard M, ten DP, Chantry A. 2006. Reversible ubiquitination regulates the Smad/TGF-beta signalling pathway. Biochem Soc Trans 34:761–763.
  • Zembutsu H, Suzuki Y, Sasaki A, Tsunoda T, Okazaki M, Yoshimoto M, et al. 2009. Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling. Int J Oncol 34:361–370.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.